1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade%s Disease) Global Clinical Trials Review, H1, 2014

Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Global Clinical Trials Review, H1, 2014" provides data on the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade%s Disease) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) to Metabolic Disorders Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) to Metabolic Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) 30
Jul 11, 2013: Alnylam Reports Positive Top-Line Results for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis 30
Mar 18, 2013: Alnylam Initiates Phase I Clinical Study For ALN-TTRsc For Treatment Of TTR-Mediated Amyloidosis 31
Feb 19, 2013: Isis Pharma Initiates Phase II/III Study Of ISIS-TTR Rx And Earns $7.5m Milestone Payment From GlaxoSmithKline 31
Aug 06, 2012: Alnylam Pharma Presents New Preclinical Data From ‘Alnylam5x15' Programs Including ALN-TTRsc For Treatment Of Transthyretin-Mediated Amyloidosis 32
Jul 16, 2012: Alnylam Reports Positive Phase I Trial Results Of ALN-TTR02 For Treatment Of TTR-Mediated Amyloidosis 33
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Pfizer Inc. 35
Clinical Trial Overview of Pfizer Inc. 35
Alnylam Pharmaceuticals, Inc. 36
Clinical Trial Overview of Alnylam Pharmaceuticals, Inc. 36
Isis Pharmaceuticals, Inc. 37
Clinical Trial Overview of Isis Pharmaceuticals, Inc. 37
GlaxoSmithKline plc 38
Clinical Trial Overview of GlaxoSmithKline plc 38
Clinical Trial Overview of Top Institutes / Government 39
Umea University 39
Clinical Trial Overview of Umea University 39
Shinshu University 40
Clinical Trial Overview of Shinshu University 40
Boston University 41
Clinical Trial Overview of Boston University 41
Ospedale Policlinico San Matteo 42
Clinical Trial Overview of Ospedale Policlinico San Matteo 42
Brigham and Women's Hospital 43
Clinical Trial Overview of Brigham and Women's Hospital 43
Kumamoto University 44
Clinical Trial Overview of Kumamoto University 44
IRCCS Policlinico San Matteo 45
Clinical Trial Overview of IRCCS Policlinico San Matteo 45
Five Key Clinical Profiles 46
Appendix 97
Abbreviations 97
Definitions 97
Research Methodology 98
Secondary Research 98
About GlobalData 99
Contact Us 99
Disclaimer 99
Source 99

List of Tables
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 11
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15
Proportion of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 16
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 19
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials by Phase, 2014* 22
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 23
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 26
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 35
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Alnylam Pharmaceuticals, Inc., 2014* 36
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Isis Pharmaceuticals, Inc., 2014* 37
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 38
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Umea University, 2014* 39
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Shinshu University, 2014* 40
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Boston University, 2014* 41
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ospedale Policlinico San Matteo, 2014* 42
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Brigham and Women's Hospital, 2014* 43
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Kumamoto University, 2014* 44
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by IRCCS Policlinico San Matteo, 2014* 45

List of Figures
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 11
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 15
Proportion of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 16
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 19
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 22
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 23
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 26
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 98

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Mucopolysaccharidosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.